In this episode of Leading Minds, host Jasmeet Sawhney sits down with Johanna Rossell, SVP and GM Rare Disease at Sumitomo Pharma America, Inc., to explore the evolving landscape of biotech and rare disease treatment. They discuss the critical need for collaboration across the entire healthcare ecosystem—including the FDA, healthcare providers, and researchers—to ensure life-changing therapies reach patients in time. Johanna shares her passion for patient impact, the power of data in demonstrating treatment value, and the importance of breaking traditional silos in pharma to drive innovation. Tune in to hear how Sumitomo is shaping the future of medicine and what it takes to lead with purpose in this dynamic industry.
IN THIS EPISODE:
[3:36] Johanna shares her professional journey through pharma
[13:06] The difference between rare diseases and regenerative medicine and traditional medicine
[16:43] Discussion of regenerative therapies and collaboration needed
[25:56] Johanna shares future innovations and what motivates her
[36:11] Advice to those who aspire to be leaders and balance personal and professional life
[41:55] Jasmine asks Johanna rapid-fire questions
KEY TAKEAWAYS:
Tissue-based regenerative medicine faces unique challenges, from donor organ sourcing to strict FDA regulations. Unlike traditional drugs, it relies on living tissues, requiring careful transport, testing, and processing to ensure safety and efficacy.
Regenerative medicine is transforming personalized treatment, especially for rare diseases. Companies like Sumitomo Pharma leverage data and patient registries to improve care while educating families and streamlining the patient journey. Evolving FDA pathways are also helping accelerate access to these groundbreaking therapies.
Introducing new treatments, especially for rare diseases, requires demonstrating clear value in clinical efficacy in long-term cost-effectiveness and improved patient outcomes. Even without complete data at launch, there must be a commitment to generating evidence over time to prove the drug's place in the standard of care.
RESOURCE LINKS:
BIOGRAPHIES:
YOUR HOST:
Jasmeet Sawhney is a life sciences industry executive, marketing leader, and serial entrepreneur with deep roots in technology and data analytics. He is currently the global head of marketing at Axtria. Jasmeet has over 20 years of experience in life sciences and has helped build and scale three successful companies. He has received several company and individual awards, including Inc 500, Deloitte Fast 500, Crain's NY Fast 50, NJBiz Fast 50, Business of the Year, SmartCEO Future 50, Top CMO, Forty Under 40, and many more.
GUEST:
Johanna has a broad and deep background across consumer goods and healthcare in the U.S. and global geographies. She has led multi-functional teams delivering strong results for companies including Procter & Gamble, Novartis, Merck, Biogen, and Sumitomo Pharma. She has successfully led new products to market in the U.S. and created integrated pre- and post-launch commercial plans, both in the U.S. and globally, including a Regenerative Medicine Advanced Therapy (RMAT) tissue-based product and several rare disease therapies. In her recent venture as Chief Commercial Officer of the biotech Enzyvant Therapeutics, she led the expansion of one of the few FDA-approved RMAT products, RETHYMIC. In her current role, she serves as SVP and GM Rare Disease at Sumitomo Pharma America, Inc.
